GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IPI Legacy Liquidation Co (OTCPK:IMPLQ) » Definitions » Net Current Asset Value

IPI Legacy Liquidation Co (IPI Legacy Liquidation Co) Net Current Asset Value : $-4.36 (As of Sep. 2023)


View and export this data going back to 2021. Start your Free Trial

What is IPI Legacy Liquidation Co Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

IPI Legacy Liquidation Co's net current asset value per share for the quarter that ended in Sep. 2023 was $-4.36.

The historical rank and industry rank for IPI Legacy Liquidation Co's Net Current Asset Value or its related term are showing as below:

During the past 4 years, the highest Price-to-Net-Current-Asset-Value Ratio of IPI Legacy Liquidation Co was 6.78. The lowest was 3.61. And the median was 3.96.

IMPLQ's Price-to-Net-Current-Asset-Value is not ranked *
in the Biotechnology industry.
Industry Median: 3.93
* Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.

IPI Legacy Liquidation Co Net Current Asset Value Historical Data

The historical data trend for IPI Legacy Liquidation Co's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IPI Legacy Liquidation Co Net Current Asset Value Chart

IPI Legacy Liquidation Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22
Net Current Asset Value
-7.19 -7.08 2.13 -2.23

IPI Legacy Liquidation Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Net Current Asset Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.19 -2.23 -3.61 -3.83 -4.36

Competitive Comparison of IPI Legacy Liquidation Co's Net Current Asset Value

For the Biotechnology subindustry, IPI Legacy Liquidation Co's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IPI Legacy Liquidation Co's Price-to-Net-Current-Asset-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IPI Legacy Liquidation Co's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where IPI Legacy Liquidation Co's Price-to-Net-Current-Asset-Value falls into.



IPI Legacy Liquidation Co Net Current Asset Value Calculation

IPI Legacy Liquidation Co's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Dec. 2022 is calculated as

Net Current Asset Value Per Share(A: Dec. 2022 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(79.809-132.707-0-0)/23.7393
=-2.23

IPI Legacy Liquidation Co's Net Current Asset Value (NCAV) per share for the quarter that ended in Sep. 2023 is calculated as

Net Current Asset Value Per Share(Q: Sep. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(23.427-126.978-0-0)/23.749
=-4.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


IPI Legacy Liquidation Co  (OTCPK:IMPLQ) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


IPI Legacy Liquidation Co Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of IPI Legacy Liquidation Co's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


IPI Legacy Liquidation Co (IPI Legacy Liquidation Co) Business Description

Traded in Other Exchanges
N/A
Address
201 Elliott Avenue West, Suite 260, Seattle, WA, USA, 98119
Impel Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on utilizing its proprietary technology to develop and commercialize transformative therapies for patients suffering from diseases with high unmet medical needs, with an initial focus on diseases of the central nervous system. The company is developing an approach to drug delivery that administers specific formulations of drugs deep into the vascular-rich upper nasal space, a gateway for therapeutic administration of a versatile range of molecules and formulations.
Executives
Vivo Capital Fund Viii, L.p. 10 percent owner 505 HAMILTON AVENUE, SUITE 200, PALO ALTO CA 94301
Michael Wayne Kalb officer: CFO 24 LUCILLE LANE, DIX HILLS NY 11746
Darren S Cline director 35 CAMBRIDGE PARK DRIVE, CAMBRIDGE MA 02140
Rajiv Amin officer: VP, Controller & Interim CFO C/O IMPEL PHARMACEUTICALS INC., 201 ELLIOTT AVENUE WEST, STE 260, SEATTLE WA 98119
Timothy S Nelson director 1024 BUBB ROAD, CUPERTINO CA 950144166
Adrian Adams director, officer: COB, CEO and President C/O AUXILIUM PHARMACEUTICALS, INC., 640 LEE ROAD, CHESTERBROOK PA 19355
Venbio Global Strategic Fund Ii L.p. 10 percent owner 1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
5am Opportunities I, L.p. 10 percent owner 501 SECOND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Opportunities I (gp), Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
5am Ventures V, L.p. 10 percent owner 2200 SAND HILL ROAD, SUITE 110, MENLO PARK CA 94025
Kkr Healthcare Strategic Growth Fund L.p. 10 percent owner C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019
Norwest Venture Partners Xiv, Lp 10 percent owner 525 UNIVERSITY AVENUE, SUITE 800, PALO ALTO CA 94301
Kkr Hcsg Gp Llc 10 percent owner C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019
5am Partners V, Llc 10 percent owner 501 2ND STREET, SUITE 350, SAN FRANCISCO CA 94107
Kkr Associates Hcsg L.p. 10 percent owner C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019